/sup 131/I-metaiodobenzylguanidine treatment in neuroblastoma: report of two cases

Journal Article · Thu Jan 01 00:00:00 EST 1987 · Med. Pediatr. Oncol.; (United States)

DOI:https://doi.org/10.1002/mpo.2950150416· OSTI ID:5721691

Cottino, F; Mussa, G C; Madon, E; Favero, A; Silvestro, L; Grazia, G

Poor results with /sup 131/I-meta-iodobenzylguanidine (MIBG) therapy have been obtained in two children with stage IV neuroblastoma treated after partial surgery and unsatisfactory combination chemotherapy. Both patients' response to treatment (four and three 1-month-spaced courses, respectively; cumulative administration of 11.9 and 9.2 GBq) has been characterized by a low isotope concentration in the primary tumor and in the multiple bone metastases and by bone marrow uptake with final severe hematological toxicity. A slight decrease in the primary tumor's volume was observed in one patient at a cumulative dose of 85 Gy; there was no change in the other's at 42 Gy. At an initial, greater isotope concentration delivering 103 Gy, some bone metastases displayed a sharp decrease in uptake that persisted in the successive courses. For both patients a progressive spreading of new tumor localization in the bones and finally in the soft tissues was observed.

• Research Organization: Nuclear Medicine Service, Torino, Italy
• OSTI ID: 5721691
• Journal Information: Med. Pediatr. Oncol.; (United States), Vol. 15:4
• Country of Publication: United States
• Language: English

Related Subjects

62 RADIOLOGY AND NUCLEAR MEDICINE
NEOPLASMS
RADIOTHERAPY
RADIOPHARMACEUTICALS
THERAPEUTIC USES
BONE MARROW
CHILDREN
IODINE 131
METASTASES
PATIENTS
SKELETON
AGE GROUPS
ANIMAL TISSUES
BETA DECAY RADIOISOTOPES
BETA-MINUS DECAY RADIOISOTOPES
BODY
DAYS LIVING RADIOISOTOPES
DISEASES
DRUGS
HEMATOPOIETIC SYSTEM
INTERMEDIATE MASS NUCLEI
IODINE ISOTOPES
ISOTOPES
LABELLED COMPOUNDS
MEDICINE
NUCLEAR MEDICINE
NUCLEI
ODD-EVEN NUCLEI
ORGANS
RADIOISOTOPES
RADIOLOGY
THERAPY
TISSUES
USES
550604* - Medicine- Unsealed Radionuclides in Therapy- (1980-)